Core Viewpoint - Yifan Pharmaceutical's product Yinikang (Dinggan Cross-linked Sodium Hyaluronate Injection) is in a rapid growth phase, with significant market potential in the treatment of osteoarthritis, particularly among the aging population in China [1][2] Group 1: Product Development and Market Position - Yifan Pharmaceutical has obtained exclusive import and distribution rights for Yinikang in China and Australia, and the product received its drug registration certificate in April 2023, allowing for official sales in China [1] - The product is expected to be included in the new national medical insurance directory by December 2023, enhancing accessibility and affordability of innovative drugs [1] - The market for osteoarthritis treatment in China is projected to reach between 102 billion to 170 billion RMB, indicating substantial growth potential for Yifan's Yinikang product [2] Group 2: Financial Performance and Growth Strategy - Yifan Pharmaceutical achieved a revenue of 5.16 billion RMB in 2024, marking a year-on-year growth of 26.84%, with domestic revenue at 3.85 billion RMB (up 34.88%) and international revenue at 1.31 billion RMB (up 7.87%) [4] - The company is focusing on internationalization, having successfully entered the EU market with its Amikacin Sulfate Injection, marking a significant milestone in its global strategy [5] - Yifan aims to increase the number of major products generating over 10 million RMB in annual sales from 29 to 35 by 2025, with specific targets for products exceeding 50 million and 100 million RMB [7] Group 3: Competitive Advantages and Future Outlook - Yifan Pharmaceutical has established a comprehensive production and sales network, positioning itself as one of the few domestic companies with a complete closed-loop capability in the pharmaceutical industry [3] - The company emphasizes innovation and internationalization as core strategies, leveraging its experience in clinical trials and regulatory processes to enhance its product line and market competitiveness [6][7] - With ongoing innovation and market expansion, Yifan is expected to achieve continuous breakthroughs in both domestic and international pharmaceutical markets [7]

科技日报讯 （记者陈曦 通讯员张华）记者6月14日从天津大学获悉，该校医学部药学院教授李楠团 队研究开发了一种新型流线型氧化锌嵌合可注射水凝胶，为骨关节炎治疗及软骨再生开辟了新路径。该 流线型水凝胶同时具备"注射时顺滑"和"植入后坚固"的双重特性。相关研究成果近日发表在国际期刊 《自然·通讯》上。 该研究聚焦于骨关节炎治疗中细胞外基质稳态失调这一关键问题，设计的流线型氧化锌嵌合可注射 水凝胶具有基质金属蛋白酶响应特性，并搭载miR-17-5p基因药物，能实现细胞外基质稳态的双向调 控。miR-17-5p基因药物是一种具有调控基因表达功能的微小RNA分子，能有效抑制骨关节炎中过度活 跃的基质金属蛋白酶。"基质金属蛋白酶是导致细胞外基质过度降解的关键因素。与传统球形结构嵌合 的水凝胶相比，流线型氧化锌结构嵌合优化了水凝胶的流变学和力学性能，赋予水凝胶高机械强度和低 流动黏度的协同优势。"李楠介绍。 该水凝胶在注射时表现出顺滑的特性，主要得益于其内部的流线型氧化锌纳米颗粒。这些纳米颗粒 具有独特的高曲率结构，使其在注射过程中能够有效地降低流体阻力。具体来说，流线型氧化锌的高曲 率结构减少了水凝胶在注射时的黏度，使其 ...